We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Zacopride in Schizophrenia: A Single-blind Serotonin Type 3 Antagonist Trial

John W. Newcomer, MD; William O. Faustman, PhD; Robert B. Zipursky, MD; John G. Csernansky, MD
Arch Gen Psychiatry. 1992;49(9):751-752. doi:10.1001/archpsyc.1992.01820090079013.
Text Size: A A A
Published online


To the Editor.—  Zacopride hydrochloride, a substituted benzamide, is a potent and selective antagonist at serotonin type 3 (5-HT3) receptors' that are found in brain areas receiving mesolimbic dopamine input.2 Much interest has been generated by reports that direct infusion of zacopride and other 5-HT3 antagonists into these mesolimbic areas in the rat inhibits dopaminergically mediated locomotor behavior without the overall depression of the central nervous system or rebound hyperlocomotion produced by conventional neuroleptic srugs.3 Zacopride has also been reported by some4 but not all5 investigators to have potent anxiolytic properties in animal models. Generally inactive at D2 dopamine receptors6 and other neurotransmitter receptors,7,8 this compound does not elevate plasma prolactin levels or cause catalepsy. Accordingly, zacopride has been hypothesized to have efficacy in the treatment of schizophrenia, without the side effects associated with conventional neuroleptic drugs. We sought to provide


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.